{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:50:12Z","timestamp":1791726612961,"version":"4.3.4"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00277-023-05457-2","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T08:02:35Z","timestamp":1695369755000},"page":"1805-1817","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["CRISPR-Cas9 system: a novel and promising era of genotherapy for beta-hemoglobinopathies, hematological malignancy, and hemophilia"],"prefix":"10.1007","volume":"103","author":[{"given":"Abdulfatah M.","family":"Alayoubi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1268-3115","authenticated-orcid":false,"given":"Zakaria Y.","family":"Khawaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A.","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois E.","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"issue":"1","key":"5457_CR1","first-page":"1","volume":"9","author":"S Jiang","year":"2019","unstructured":"Jiang S, Shen QW (2019) Principles of gene editing techniques and applications in animal husbandry. 3. Biotech 9(1):1\u20139","journal-title":"Biotech"},{"issue":"3","key":"5457_CR2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/0092-8674(87)90646-5","volume":"51","author":"KR Thomas","year":"1987","unstructured":"Thomas KR, Capecchi MR (1987) Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell. 51(3):503\u2013512","journal-title":"Cell."},{"issue":"5","key":"5457_CR3","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3324\/haematol.2018.211359","volume":"104","author":"E Gonz\u00e1lez-Romero","year":"2019","unstructured":"Gonz\u00e1lez-Romero E, Mart\u00ednez-Valiente C, Garc\u00eda-Ruiz C, V\u00e1zquez-Manrique RP, Cervera J, Sanjuan-Pla A (2019) CRISPR to fix bad blood: a new tool in basic and clinical hematology. Haematologica. 104(5):881","journal-title":"Haematologica."},{"issue":"1","key":"5457_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.21775\/cimb.028.047","volume":"28","author":"HI Ahmad","year":"2018","unstructured":"Ahmad HI, Ahmad MJ, Asif AR, Adnan M, Iqbal MK, Mehmood K, Muhammad SA, Bhuiyan AA, Elokil A, Du X, Zhao C (2018) A review of CRISPR-based genome editing: survival, evolution and challenges. Curr Issues Mol Biol 28(1):47\u201368","journal-title":"Curr Issues Mol Biol"},{"issue":"5","key":"5457_CR5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41434-021-00247-9","volume":"29","author":"Y Chen","year":"2022","unstructured":"Chen Y, Wen R, Yang Z, Chen Z (2022) Genome editing using CRISPR\/Cas9 to treat hereditary hematological disorders. Gene Ther 29(5):207\u2013216","journal-title":"Gene Ther"},{"key":"5457_CR6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2147\/BTT.S326422","volume":"15","author":"M Asmamaw","year":"2021","unstructured":"Asmamaw M, Zawdie B (2021) Mechanism and applications of CRISPR\/Cas-9-mediated genome editing. Biol Targets Ther 15:353","journal-title":"Biol Targets Ther"},{"issue":"7","key":"5457_CR7","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1111\/jcmm.14916","volume":"24","author":"FV Jacinto","year":"2020","unstructured":"Jacinto FV, Link W, Ferreira BI (2020) CRISPR\/Cas9-mediated genome editing: from basic research to translational medicine. J Cell Mol Med 24(7):3766\u20133778","journal-title":"J Cell Mol Med"},{"issue":"7","key":"5457_CR8","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1093\/nar\/gkac192","volume":"50","author":"V Konstantakos","year":"2022","unstructured":"Konstantakos V, Nentidis A, Krithara A, Paliouras G (2022) CRISPR\u2013Cas9 gRNA efficiency prediction: an overview of predictive tools and the role of deep learning. Nucleic Acids Res 50(7):3616\u20133637","journal-title":"Nucleic Acids Res"},{"key":"5457_CR9","doi-asserted-by":"crossref","unstructured":"Tahir T, Ali Q, Rashid MS, Malik A (2020) The journey of CRISPR-Cas9 from bacterial defense mechanism to a gene editing tool in both animals and plants.\u00a0Biol Clin Sci Res J\u00a02020(1)","DOI":"10.54112\/bcsrj.v2020i1.17"},{"issue":"1","key":"5457_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00424-020-02497-9","volume":"473","author":"L Westermann","year":"2021","unstructured":"Westermann L, Neubauer B, K\u00f6ttgen M (2021) Nobel Prize 2020 in Chemistry honors CRISPR: a tool for rewriting the code of life. Pflugers Arch - Eur J Physiol 473(1):1\u20132","journal-title":"Pflugers Arch - Eur J Physiol"},{"key":"5457_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-7299-9_8","volume-title":"Gene and cell therapies for beta-globinopathies. Advances in experimental medicine and biology","author":"MH Porteus","year":"2017","unstructured":"Porteus MH (2017) Genome editing for the \u03b2-hemoglobinopathies. In: Malik P, Tisdale J (eds) Gene and cell therapies for beta-globinopathies. Advances in experimental medicine and biology, vol 1013. Springer, New York, NY. https:\/\/doi.org\/10.1007\/978-1-4939-7299-9_8"},{"key":"5457_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/HS9.0000000000000479","volume":"4","author":"JB Kunz","year":"2020","unstructured":"Kunz JB, Kulozik AE (2020) Gene therapy of the hemoglobinopathies. HemaSphere 4:5","journal-title":"HemaSphere"},{"issue":"3","key":"5457_CR13","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3390\/jcm10030482","volume":"10","author":"G Frati","year":"2021","unstructured":"Frati G, Miccio A (2021) Genome editing for \u03b2-hemoglobinopathies: advances and challenges. J Clin Med 10(3):482","journal-title":"J Clin Med"},{"issue":"1","key":"5457_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/cancers14010087","volume":"14","author":"A Sochacka-\u0106wik\u0142a","year":"2021","unstructured":"Sochacka-\u0106wik\u0142a A, M\u0105czy\u0144ski M, Regiec A (2021) FDA-approved drugs for hematological malignancies\u2014the last decade review. Cancers 14(1):87","journal-title":"Cancers"},{"key":"5457_CR15","first-page":"3","volume-title":"Principles of molecular biology and oncogenesis. In Precision molecular pathology of neoplastic pediatric diseases","author":"RL Stewart","year":"2018","unstructured":"Stewart RL, Koo SC, Furtado LV (2018) Principles of molecular biology and oncogenesis. In Precision molecular pathology of neoplastic pediatric diseases. Springer, Cham, pp 3\u20138"},{"key":"5457_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-017-9078-9_23","volume-title":"Translation and its regulation in cancer biology and medicine","author":"M Reschke","year":"2014","unstructured":"Reschke M, Seitzer N, Clohessy J, Pandolfi P (2014) Hematological malignancies and premalignant conditions. In: Parsyan A (ed) Translation and its regulation in cancer biology and medicine. Springer, Dordrecht. https:\/\/doi.org\/10.1007\/978-94-017-9078-9_23"},{"key":"5457_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-24725-6_12","volume-title":"Cancer biomarkers in body fluids","author":"GD Dakubo","year":"2019","unstructured":"Dakubo GD (2019) Hematologic malignancy biomarkers in proximal fluids. In: Cancer biomarkers in body fluids. Springer, Cham. https:\/\/doi.org\/10.1007\/978-3-030-24725-6_12"},{"key":"5457_CR18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jconrel.2018.08.034","volume":"287","author":"AK Deshantri","year":"2018","unstructured":"Deshantri AK, Moreira AV, Ecker V, Mandhane SN, Schiffelers RM, Buchner M, Fens MH (2018) Nanomedicines for the treatment of hematological malignancies. J Control Release 287:194\u2013215","journal-title":"J Control Release"},{"issue":"1","key":"5457_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-021-00278-x","volume":"7","author":"E Berntorp","year":"2021","unstructured":"Berntorp E, Fischer K, Hart DP, Mancuso ME, Stephensen D, Shapiro AD, Blanchette V (2021) Haemophilia. Nat Rev Dis Primers 7(1):1\u20139","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"5457_CR20","first-page":"389","volume":"133","author":"AC Weyand","year":"2019","unstructured":"Weyand AC, Pipe SW (2019) New therapies for hemophilia. Blood J American Soc Hematol 133(5):389\u2013398","journal-title":"Blood J American Soc Hematol"},{"issue":"9","key":"5457_CR21","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00439-016-1699-x","volume":"135","author":"CY Park","year":"2016","unstructured":"Park CY, Lee DR, Sung JJ, Kim DW (2016) Genome-editing technologies for gene correction of hemophilia. Hum Genet 135(9):977\u2013981","journal-title":"Hum Genet"},{"key":"5457_CR22","doi-asserted-by":"crossref","unstructured":"Lone BA, Karna SKL, Ahmad F, Shahi N, Pokharel YR (2018) CRISPR\/CAS9 System: a bacterial tailor for genomic engineering.\u00a0Genet Res Int 2018:1\u201317","DOI":"10.1155\/2018\/3797214"},{"issue":"3","key":"5457_CR23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00005-016-0427-5","volume":"65","author":"M Hryhorowicz","year":"2017","unstructured":"Hryhorowicz M, Lipi\u0144ski D, Zeyland J, S\u0142omski R (2017) CRISPR\/Cas9 immune system as a tool for genome engineering. Arch Immunol Ther Exp 65(3):233\u2013240","journal-title":"Arch Immunol Ther Exp"},{"issue":"1","key":"5457_CR24","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","volume":"46","author":"F Jiang","year":"2017","unstructured":"Jiang F, Doudna JA (2017) CRISPR-Cas9 structures and mechanisms. Annu Rev Biophys 46(1):505\u2013529","journal-title":"Annu Rev Biophys"},{"key":"5457_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-022-01518-8","volume":"21","author":"SW Wang","year":"2022","unstructured":"Wang SW, Gao C, Zheng YM et al (2022) Current applications and future perspective of CRISPR\/Cas9 gene editing in cancer. Mol Cancer 21:57. https:\/\/doi.org\/10.1186\/s12943-022-01518-8","journal-title":"Mol Cancer"},{"key":"5457_CR26","doi-asserted-by":"publisher","first-page":"116636","DOI":"10.1016\/j.lfs.2019.116636","volume":"232","author":"D Gupta","year":"2019","unstructured":"Gupta D, Bhattacharjee O, Mandal D, Sen MK, Dey D, Dasgupta A, Kazi TA, Gupta R, Sinharoy S, Acharya K, Chattopadhyay D (2019) CRISPR-Cas9 system: a new-fangled dawn in gene editing. Life Sci 232:116636","journal-title":"Life Sci"},{"issue":"6213","key":"5457_CR27","doi-asserted-by":"publisher","first-page":"1258096","DOI":"10.1126\/science.1258096","volume":"346","author":"JA Doudna","year":"2014","unstructured":"Doudna JA, Charpentier E (2014) The new frontier of genome engineering with CRISPR-Cas9. Science 346(6213):1258096","journal-title":"Science"},{"issue":"266","key":"5457_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jconrel.2017.09.012","volume":"28","author":"C Liu","year":"2017","unstructured":"Liu C, Zhang L, Liu H, Cheng K (2017 Nov) Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications. J Control Release 28(266):17\u201326","journal-title":"J Control Release"},{"issue":"24","key":"5457_CR29","doi-asserted-by":"publisher","first-page":"9604","DOI":"10.3390\/ijms21249604","volume":"21","author":"E Janik","year":"2020","unstructured":"Janik E, Niemcewicz M, Ceremuga M, Krzowski L, Saluk-Bijak J, Bijak M (2020) Various aspects of a gene editing system\u2014crispr\u2013cas9. Int J Mol Sci 21(24):9604","journal-title":"Int J Mol Sci"},{"issue":"4","key":"5457_CR30","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1002\/jcp.30064","volume":"236","author":"B Zhang","year":"2021","unstructured":"Zhang B (2021) CRISPR\/Cas gene therapy. J Cell Physiol 236(4):2459\u20132481","journal-title":"J Cell Physiol"},{"issue":"1","key":"5457_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-021-01431-6","volume":"20","author":"H Zhang","year":"2021","unstructured":"Zhang H, Qin C, An C, Zheng X, Wen S, Chen W, Liu X, Lv Z, Yang P, Xu W, Gao W (2021) Application of the CRISPR\/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer. Mol Cancer 20(1):1\u201322","journal-title":"Mol Cancer"},{"key":"5457_CR32","doi-asserted-by":"publisher","first-page":"118969","DOI":"10.1016\/j.lfs.2020.118969","volume":"267","author":"A Ghaemi","year":"2021","unstructured":"Ghaemi A, Bagheri E, Abnous K, Taghdisi SM, Ramezani M, Alibolandi M (2021) CRISPR-cas9 genome editing delivery systems for targeted cancer therapy. Life Sci 267:118969","journal-title":"Life Sci"},{"issue":"5","key":"5457_CR33","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.stem.2020.10.014","volume":"27","author":"D Hendriks","year":"2020","unstructured":"Hendriks D, Clevers H, Artegiani B (2020) CRISPR-Cas tools and their application in genetic engineering of human stem cells and organoids. Cell Stem Cell 27(5):705\u2013731","journal-title":"Cell Stem Cell"},{"issue":"7603","key":"5457_CR34","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","volume":"533","author":"AC Komor","year":"2016","unstructured":"Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR (2016) Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533(7603):420\u2013424","journal-title":"Nature"},{"key":"5457_CR35","first-page":"487","volume-title":"Seminars in perinatology","author":"F Memi","year":"2018","unstructured":"Memi F, Ntokou A, Papangeli I. CRISPR\/Cas9 gene-editing: research technologies, clinical applications and ethical considerations. Seminars in perinatology 2018 (42 8, 487-500). WB Saunders"},{"issue":"17","key":"5457_CR36","doi-asserted-by":"publisher","first-page":"6240","DOI":"10.3390\/ijms21176240","volume":"21","author":"A Kantor","year":"2020","unstructured":"Kantor A, McClements ME, MacLaren RE (2020) CRISPR-Cas9 DNA base-editing and prime-editing. Int J Mol Sci 21(17):6240","journal-title":"Int J Mol Sci"},{"issue":"7785","key":"5457_CR37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, Chen PJ, Wilson C, Newby GA, Raguram A, Liu DR (2019) Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576(7785):149\u2013157","journal-title":"Nature"},{"issue":"7","key":"5457_CR38","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","volume":"38","author":"AV Anzalone","year":"2020","unstructured":"Anzalone AV, Koblan LW, Liu DR (2020) Genome editing with CRISPR\u2013Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol 38(7):824\u2013844","journal-title":"Nat Biotechnol"},{"key":"5457_CR39","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-pathmechdis-012418-012838","volume":"14","author":"P Sundd","year":"2019","unstructured":"Sundd P, Gladwin MT, Novelli EM (2019) Pathophysiology of sickle cell disease. Annu Rev Pathol 14:263","journal-title":"Annu Rev Pathol"},{"key":"5457_CR40","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1146\/annurev-genom-083117-021320","volume":"19","author":"TN Williams","year":"2018","unstructured":"Williams TN, Thein SL (2018) Sickle cell anemia and its phenotypes. Annu Rev Genomics Hum Genet 19:113\u2013147","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"6483","key":"5457_CR41","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1126\/science.aba3827","volume":"367","author":"JF Tisdale","year":"2020","unstructured":"Tisdale JF, Thein SL, Eaton WA (2020) Treating sickle cell anemia. Science 367(6483):1198\u20131199","journal-title":"Science"},{"key":"5457_CR42","unstructured":"Needs T, Gonzalez-Mosquera LF,\u00a0 Lynch DT (2022) Beta thalassemia. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL)"},{"issue":"1","key":"5457_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40246-018-0187-x","volume":"13","author":"C Constantinou","year":"2019","unstructured":"Constantinou C, Spella M, Chondrou V, Patrinos GP, Papachatzopoulou A, Sgourou A (2019) The multi-faceted functioning portrait of LRF\/ZBTB7A. Hum Gen 13(1):1\u20134","journal-title":"Hum Gen"},{"issue":"12","key":"5457_CR44","doi-asserted-by":"publisher","first-page":"6677","DOI":"10.1172\/JCI140189","volume":"130","author":"S Demirci","year":"2020","unstructured":"Demirci S, Zeng J, Wu Y, Uchida N, Shen AH, Pellin D, Gamer J, Yapundich M, Drysdale C, Bonanno J, Bonifacino AC (2020) BCL11A enhancer\u2013edited hematopoietic stem cells persist in rhesus monkeys without toxicity. J Clin Invest 130(12):6677\u20136687","journal-title":"J Clin Invest"},{"key":"5457_CR45","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.gde.2015.08.001","volume":"33","author":"DE Bauer","year":"2015","unstructured":"Bauer DE, Orkin SH (2015) Hemoglobin switching\u2019s surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin. Curr Opin Genet Dev 33:62\u201370","journal-title":"Curr Opin Genet Dev"},{"issue":"5","key":"5457_CR46","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/bjh.15851","volume":"185","author":"TI Jensen","year":"2019","unstructured":"Jensen TI, Axelgaard E, Bak RO (2019) Therapeutic gene editing in haematological disorders with CRISPR\/Cas9. Br J Haematol 185(5):821\u2013835","journal-title":"Br J Haematol"},{"issue":"13","key":"5457_CR47","doi-asserted-by":"publisher","first-page":"848261","DOI":"10.3389\/fphys.2022.848261","volume":"28","author":"O Quintana-Bustamante","year":"2022","unstructured":"Quintana-Bustamante O, Fa\u00f1anas-Baquero S, Dessy-Rodriguez M, Ojeda-P\u00e9rez I, Segovia JC (2022) Gene editing for inherited red blood cell diseases. Front Physiol 28(13):848261","journal-title":"Front Physiol"},{"issue":"7577","key":"5457_CR48","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nature15521","volume":"527","author":"MC Canver","year":"2015","unstructured":"Canver MC, Smith EC, Sher F, Pinello L, Sanjana NE, Shalem O, Chen DD, Schupp PG, Vinjamur DS, Garcia SP, Luc S (2015) BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature 527(7577):192\u2013197","journal-title":"Nature"},{"issue":"4","key":"5457_CR49","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41591-020-0790-y","volume":"26","author":"J Zeng","year":"2020","unstructured":"Zeng J, Wu Y, Ren C, Bonanno J, Shen AH, Shea D, Gehrke JM, Clement K, Luk K, Yao Q, Kim R (2020) Therapeutic base editing of human hematopoietic stem cells. Nat Med 26(4):535\u2013541","journal-title":"Nat Med"},{"issue":"5","key":"5457_CR50","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41591-019-0401-y","volume":"25","author":"Y Wu","year":"2019","unstructured":"Wu Y, Zeng J, Roscoe BP, Liu P, Yao Q, Lazzarotto CR, Clement K, Cole MA, Luk K, Baricordi C, Shen AH (2019) Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nat Med 25(5):776\u2013783","journal-title":"Nat Med"},{"issue":"7","key":"5457_CR51","doi-asserted-by":"publisher","first-page":"eaay9392","DOI":"10.1126\/sciadv.aay9392","volume":"6","author":"L Weber","year":"2020","unstructured":"Weber L, Frati G, Felix T, Hardouin G, Casini A, Wollenschlaeger C, Meneghini V, Masson C, De Cian A, Chalumeau A, Mavilio F (2020) Editing a \u03b3-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype. Sci Adv 6(7):eaay9392","journal-title":"Sci Adv"},{"issue":"6270","key":"5457_CR52","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1126\/science.aad3312","volume":"351","author":"T Masuda","year":"2016","unstructured":"Masuda T, Wang X, Maeda M, Canver MC, Sher F, Funnell AP, Fisher C, Suciu M, Martyn GE, Norton LJ, Zhu C (2016) Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin. Science 351(6270):285\u2013289","journal-title":"Science"},{"issue":"3","key":"5457_CR53","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul H, Altshuler D, Cappellini MD, Chen YS, Domm J, Eustace BK, Foell J, de la Fuente J, Grupp S, Handgretinger R, Ho TW (2021) CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. N Engl J Med 384(3):252\u2013260","journal-title":"N Engl J Med"},{"issue":"8","key":"5457_CR54","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1038\/s41591-022-01906-z","volume":"28","author":"B Fu","year":"2022","unstructured":"Fu B, Liao J, Chen S, Li W, Wang Q, Hu J, Yang F, Hsiao S, Jiang Y, Wang L, Chen F (2022) CRISPR\u2013Cas9-mediated gene editing of the BCL11A enhancer for pediatric \u03b20\/\u03b20 transfusion-dependent \u03b2-thalassemia. Nat Med 28(8):1573\u20131580","journal-title":"Nat Med"},{"issue":"3","key":"5457_CR55","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2029392","volume":"384","author":"EB Esrick","year":"2021","unstructured":"Esrick EB, Lehmann LE, Biffi A, Achebe M, Brendel C, Ciuculescu MF, Daley H, MacKinnon B, Morris E, Federico A, Abriss D (2021) Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease. N Engl J Med 384(3):205\u2013215","journal-title":"N Engl J Med"},{"issue":"2","key":"5457_CR56","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/GIM.0b013e3181cd68ed","volume":"12","author":"A Cao","year":"2010","unstructured":"Cao A, Galanello R (2010) Beta-thalassemia. Genet Med 12(2):61\u201376","journal-title":"Genet Med"},{"key":"5457_CR57","doi-asserted-by":"crossref","unstructured":"Thein SL (2017) Genetic basis and genetic modifiers of \u03b2-thalassemia and sickle cell disease. Gene and Cell Therapies for Beta-Globinopathies 27\u201357","DOI":"10.1007\/978-1-4939-7299-9_2"},{"issue":"9","key":"5457_CR58","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1089\/scd.2014.0347","volume":"24","author":"B Song","year":"2015","unstructured":"Song B, Fan Y, He W, Zhu D, Niu X, Wang D, Ou Z, Luo M, Sun X (2015) Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR\/Cas9 system. Stem Cells Dev 24(9):1053\u20131065","journal-title":"Stem Cells Dev"},{"issue":"32","key":"5457_CR59","doi-asserted-by":"publisher","first-page":"16576","DOI":"10.1074\/jbc.M116.719237","volume":"291","author":"X Niu","year":"2016","unstructured":"Niu X, He W, Song B, Ou Z, Fan D, Chen Y, Fan Y, Sun X (2016) Combining single strand oligodeoxynucleotides and CRISPR\/Cas9 to correct gene mutations in \u03b2-thalassemia-induced pluripotent stem cells. J Biol Chem 291(32):16576\u201316585","journal-title":"J Biol Chem"},{"issue":"9","key":"5457_CR60","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1101\/gr.173427.114","volume":"24","author":"F Xie","year":"2014","unstructured":"Xie F, Ye L, Chang JC, Beyer AI, Wang J, Muench MO, Kan YW (2014) Seamless gene correction of \u03b2-thalassemia mutations in patient-specific iPSCs using CRISPR\/Cas9 and piggyBac. Genome Res 24(9):1526\u20131533","journal-title":"Genome Res"},{"issue":"1","key":"5457_CR61","first-page":"1","volume":"5","author":"P Xu","year":"2015","unstructured":"Xu P, Tong Y, Liu XZ, Wang TT, Cheng L, Wang BY, Lv X, Huang Y, Liu DP (2015) Both TALENs and CRISPR\/Cas9 directly target the HBB IVS2\u2013654 (C> T) mutation in \u03b2-thalassemia-derived iPSCs. Sci Rep 5(1):1\u20132","journal-title":"Sci Rep"},{"issue":"7629","key":"5457_CR62","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature20134","volume":"539","author":"DP Dever","year":"2016","unstructured":"Dever DP et al (2016) CRISPR\/Cas9 \u03b2-globin gene targeting in human haematopoietic stem cells. Nature 539(7629):384\u2013389","journal-title":"Nature"},{"issue":"1","key":"5457_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-20909-x","volume":"12","author":"AC Wilkinson","year":"2021","unstructured":"Wilkinson AC, Dever DP, Baik R, Camarena J, Hsu I, Charlesworth CT, Morita C, Nakauchi H, Porteus MH (2021) Cas9-AAV6 gene correction of beta-globin in autologous HSCs improves sickle cell disease erythropoiesis in mice. Nat Commun 12(1):1\u20139","journal-title":"Nat Commun"},{"issue":"598","key":"5457_CR64","doi-asserted-by":"publisher","first-page":"eabf2444","DOI":"10.1126\/scitranslmed.abf2444","volume":"13","author":"A Lattanzi","year":"2021","unstructured":"Lattanzi A, Camarena J, Lahiri P, Segal H, Srifa W, Vakulskas CA, Frock RL, Kenrick J, Lee C, Talbott N, Skowronski J (2021) Development of \u03b2-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. Sci Transl Med 13(598):eabf2444","journal-title":"Sci Transl Med"},{"issue":"1","key":"5457_CR65","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/sctm.17-0066","volume":"7","author":"L Cai","year":"2018","unstructured":"Cai L, Bai H, Mahairaki V, Gao Y, He C, Wen Y, Jin YC, Wang Y, Pan RL, Qasba A, Ye Z (2018) A universal approach to correct various HBB gene mutations in human stem cells for gene therapy of beta-thalassemia and sickle cell disease. Stem Cells Transl Med 7(1):87\u201397","journal-title":"Stem Cells Transl Med"},{"key":"5457_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","volume":"5","author":"H Li","year":"2020","unstructured":"Li H, Yang Y, Hong W et al (2020) Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Sig Transduct Target Ther 5:1. https:\/\/doi.org\/10.1038\/s41392-019-0089-y","journal-title":"Sig Transduct Target Ther"},{"key":"5457_CR67","doi-asserted-by":"crossref","unstructured":"Iyer DN, Schimmer AD, Chang H (2023) Applying CRISPR-Cas9 screens to dissect hematological malignancies. Blood Adv 7(10):2252\u20132270","DOI":"10.1182\/bloodadvances.2022008966"},{"issue":"4","key":"5457_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM (2021) CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 11(4):1","journal-title":"Blood Cancer J"},{"issue":"6","key":"5457_CR69","first-page":"2183","volume":"42","author":"R Mohanty","year":"2019","unstructured":"Mohanty R, Chowdhury CR, Arega S, Sen P, Ganguly P, Ganguly N (2019) CAR T cell therapy: a new era for cancer treatment. Oncol Rep 42(6):2183\u20132195","journal-title":"Oncol Rep"},{"issue":"2","key":"5457_CR70","doi-asserted-by":"publisher","first-page":"326","DOI":"10.7150\/jca.48976","volume":"12","author":"D Han","year":"2021","unstructured":"Han D, Xu Z, Zhuang Y, Ye Z, Qian Q (2021) Current progress in CAR-T cell therapy for hematological malignancies. J Cancer 12(2):326","journal-title":"J Cancer"},{"issue":"1","key":"5457_CR71","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/cpt.1674","volume":"107","author":"SA Holstein","year":"2020","unstructured":"Holstein SA, Lunning MA (2020) CAR T-cell therapy in hematologic malignancies: a voyage in progress. Clin Pharmacol Ther 107(1):112\u2013122","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"5457_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-022-01559-z","volume":"21","author":"A Dimitri","year":"2022","unstructured":"Dimitri A, Herbst F, Fraietta JA (2022) Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol Cancer 21(1):1\u20133","journal-title":"Mol Cancer"},{"issue":"1","key":"5457_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-021-02510-7","volume":"12","author":"E Razeghian","year":"2021","unstructured":"Razeghian E, Nasution MK, Rahman HS, Gardanova ZR, Abdelbasset WK, Aravindhan S, Bokov DO, Suksatan W, Nakhaei P, Shariatzadeh S, Marofi F (2021) A deep insight into CRISPR\/Cas9 application in CAR-T cell-based tumor immunotherapies. Stem Cell Res Ther 12(1):1\u20137","journal-title":"Stem Cell Res Ther"},{"key":"5457_CR74","doi-asserted-by":"publisher","first-page":"100641","DOI":"10.1016\/j.ctarc.2022.100641","volume":"27","author":"A Khan","year":"2022","unstructured":"Khan A, Sarkar E (2022) Review CRISPR\/Cas9 encouraged CAR-T cell immunotherapy reporting efficient and safe clinical results towards cancer. Cancer Treat Res Commun 27:100641","journal-title":"Cancer Treat Res Commun"},{"issue":"11","key":"5457_CR75","first-page":"5853","volume":"17","author":"L Wang","year":"2022","unstructured":"Wang L, Chen Y, Liu X, Li Z, Dai X (2022) The application of CRISPR\/Cas9 technology for cancer immunotherapy: current status and problems. Front Oncol 17(11):5853","journal-title":"Front Oncol"},{"issue":"7","key":"5457_CR76","first-page":"697","volume":"133","author":"RM Sterner","year":"2019","unstructured":"Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, Hansen MJ, Jin F, Ayasoufi K, Hefazi M, Schick KJ (2019) GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood J American Soc Hematol 133(7):697\u2013709","journal-title":"Blood J American Soc Hematol"},{"key":"5457_CR77","doi-asserted-by":"crossref","unstructured":"Tang N, Cheng C, Zhang X, Qiao M, Li N, Mu W, Wei XF, Han W, Wang H (2020) TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI insight 5(4)","DOI":"10.1172\/jci.insight.133977"},{"issue":"7643","key":"5457_CR78","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, Cunanan KM, Odak A, G\u00f6nen M, Sadelain M (2017) Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature 543(7643):113\u2013117","journal-title":"Nature"},{"issue":"5","key":"5457_CR79","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.ymthe.2018.02.025","volume":"26","author":"C Georgiadis","year":"2018","unstructured":"Georgiadis C, Preece R, Nickolay L, Etuk A, Petrova A, Ladon D, Danyi A, Humphryes-Kirilov N, Ajetunmobi A, Kim D, Kim JS (2018) Long terminal repeat CRISPR-CAR-coupled \u201cuniversal\u201d T cells mediate potent anti-leukemic effects. Mol Ther 26(5):1215\u20131227","journal-title":"Mol Ther"},{"issue":"1","key":"5457_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-00462-8","volume":"7","author":"LJ Rupp","year":"2017","unstructured":"Rupp LJ, Schumann K, Roybal KT, Gate RE, Ye CJ, Lim WA, Marson A (2017) CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep 7(1):1","journal-title":"Sci Rep"},{"issue":"12","key":"5457_CR81","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1182\/blood.2020005185","volume":"136","author":"D Stenger","year":"2020","unstructured":"Stenger D, Stief TA, Kaeuferle T, Willier S, Rataj F, Schober K, Vick B, Lotfi R, Wagner B, Gr\u00fcnewald TG, Kobold S (2020) Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR\/Cas9-mediated TCR knockout CAR. Blood 136(12):1407\u20131418","journal-title":"Blood"},{"key":"5457_CR82","doi-asserted-by":"crossref","unstructured":"Stadtmauer EA, Cohen AD, Weber K, Lacey SF, Gonzalez VE, Melenhorst JJ, June CH (2019) First-in-human assessment of feasibility and safety of multiplexed genetic engineering of autologous T cells expressing NY-ESO-1 TCR and CRISPR\/Cas9 gene edited to eliminate endogenous TCR and PD-1 (NYCE T cells) in advanced multiple myeloma (MM) and sarcoma. Blood 134:49","DOI":"10.1182\/blood-2019-122374"},{"issue":"9","key":"5457_CR83","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1158\/2326-6066.CIR-20-0675","volume":"9","author":"G Wei","year":"2021","unstructured":"Wei G, Zhang Y, Zhao H, Wang Y, Liu Y, Liang B, Wang X, Xu H, Cui J, Wu W, Zhao K (2021) CD19\/CD22 dual-targeted CAR T-cell therapy for relapsed\/refractory aggressive B-cell lymphoma: a safety and efficacy study. Cancer Immunol Res 9(9):1061\u20131070","journal-title":"Cancer Immunol Res"},{"issue":"13","key":"5457_CR84","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1007\/s00018-019-03084-7","volume":"76","author":"S Asada","year":"2019","unstructured":"Asada S, Fujino T, Goyama S, Kitamura T (2019) The role of ASXL1 in hematopoiesis and myeloid malignancies. Cell Mol Life Sci 76(13):2511\u20132523","journal-title":"Cell Mol Life Sci"},{"issue":"42","key":"5457_CR85","doi-asserted-by":"publisher","first-page":"44061","DOI":"10.18632\/oncotarget.6392","volume":"6","author":"S Valletta","year":"2015","unstructured":"Valletta S, Dolatshad H, Bartenstein M, Yip BH, Bello E, Gordon S, Yu Y, Shaw J, Roy S, Scifo L, Schuh A (2015) ASXL1 mutation correction by CRISPR\/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts. Oncotarget 6(42):44061","journal-title":"Oncotarget"},{"issue":"10","key":"5457_CR86","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3389\/fonc.2020.00448","volume":"3","author":"SL Felce","year":"2020","unstructured":"Felce SL, Anderson AP, Maguire S, Gascoyne DM, Armstrong RN, Wong KK, Li D, Banham AH (2020) CRISPR\/Cas9-mediated Foxp1 silencing restores immune surveillance in an immunocompetent A20 lymphoma model. Front Oncol 3(10):448","journal-title":"Front Oncol"},{"issue":"9","key":"5457_CR87","doi-asserted-by":"publisher","first-page":"875","DOI":"10.18632\/oncotarget.27506","volume":"11","author":"S Schlager","year":"2020","unstructured":"Schlager S, Salomon C, Olt S, Albrecht C, Ebert A, Bergner O, Wachter J, Trapani F, Gerlach D, Voss T, Traunbauer A (2020) Inducible knock-out of BCL6 in lymphoma cells results in tumor stasis. Oncotarget 11(9):875","journal-title":"Oncotarget"},{"issue":"1","key":"5457_CR88","doi-asserted-by":"publisher","first-page":"e0245349","DOI":"10.1371\/journal.pone.0245349","volume":"16","author":"M Khaled","year":"2021","unstructured":"Khaled M, Moustafa AS, El-Khazragy N, Ahmed MI, Abd Elkhalek MA, El-Salahy EM (2021) CRISPR\/Cas9 mediated knock-out of VPREB1 gene induces a cytotoxic effect in myeloma cells. PLoS One 16(1):e0245349","journal-title":"PLoS One"},{"issue":"4","key":"5457_CR89","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.celrep.2016.09.079","volume":"17","author":"K Tzelepis","year":"2016","unstructured":"Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, Mupo A, Grinkevich V, Li M, Mazan M, Gozdecka M (2016) A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia. Cell Rep 17(4):1193\u20131205","journal-title":"Cell Rep"},{"issue":"17","key":"5457_CR90","doi-asserted-by":"publisher","first-page":"5072","DOI":"10.1182\/bloodadvances.2022007250","volume":"6","author":"FE Mercier","year":"2022","unstructured":"Mercier FE, Shi J, Sykes DB, Oki T, Jankovic M, Man CH, Kfoury YS, Miller E, He S, Zhu A, Vasic R (2022) In vivo genome-wide CRISPR screening in murine acute myeloid leukemia uncovers microenvironmental dependencies. Blood Adv 6(17):5072\u20135084","journal-title":"Blood Adv"},{"issue":"1","key":"5457_CR91","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s12185-018-2513-4","volume":"111","author":"T Ohmori","year":"2020","unstructured":"Ohmori T (2020) Advances in gene therapy for hemophilia: basis, current status, and future perspectives. Int J Hematol 111(1):31\u201341","journal-title":"Int J Hematol"},{"issue":"2","key":"5457_CR92","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.stem.2015.07.001","volume":"17","author":"CY Park","year":"2015","unstructured":"Park CY, Kim DH, Son JS, Sung JJ, Lee J, Bae S, Kim JH, Kim DW, Kim JS (2015) Functional correction of large factor VIII gene chromosomal inversions in hemophilia A patient-derived iPSCs using CRISPR-Cas9. Cell Stem Cell 17(2):213\u2013220","journal-title":"Cell Stem Cell"},{"issue":"136","key":"5457_CR93","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2020-142679","volume":"5","author":"LV Dinh","year":"2020","unstructured":"Dinh LV, Fine E, Ameri A, Luu BW, Kumar S, Diego VP, Curran JE, Peralta JM, Mead H, Escobar MA, Williams-Blangero S (2020) Specific correction of the intron-22 inverted factor VIII gene in autologous blood outgrowth endothelial cells from patients with severe hemophilia A. Blood 5(136):30\u201331","journal-title":"Blood"},{"issue":"9","key":"5457_CR94","doi-asserted-by":"publisher","first-page":"672564","DOI":"10.3389\/fcell.2021.672564","volume":"16","author":"S Luo","year":"2021","unstructured":"Luo S, Li Z, Dai X, Zhang R, Liang Z, Li W, Zeng M, Su J, Wang J, Liang X, Wu Y (2021) CRISPR\/Cas9-mediated in vivo genetic correction in a mouse model of hemophilia A. Front Cell Dev Biol 16(9):672564","journal-title":"Front Cell Dev Biol"},{"key":"5457_CR95","doi-asserted-by":"crossref","unstructured":"Tantawy AA\u00a0 (2010) Molecular genetics of hemophilia A: Clinical perspectives.\u00a0Egypt J Med Hum Genet 11(2)","DOI":"10.1016\/j.ejmhg.2010.10.005"},{"issue":"24","key":"5457_CR96","first-page":"3697","volume":"123","author":"LA Everett","year":"2014","unstructured":"Everett LA, Cleuren AC, Khoriaty RN, Ginsburg D (2014) Murine coagulation factor VIII is synthesized in endothelial cells. Blood J American Soc Hematol 123(24):3697\u20133705","journal-title":"Blood J American Soc Hematol"},{"issue":"1","key":"5457_CR97","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/jth.12412","volume":"12","author":"T Shahani","year":"2014","unstructured":"Shahani T, Covens K, Lavend'Homme R, Jazouli N, Sokal E, Peerlinck K, Jacquemin M (2014) Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII. J Thromb Haemost 12(1):36\u201342","journal-title":"J Thromb Haemost"},{"issue":"1","key":"5457_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-019-1907-9","volume":"20","author":"JP Zhang","year":"2019","unstructured":"Zhang JP, Cheng XX, Zhao M, Li GH, Xu J, Zhang F, Yin MD, Meng FY, Dai XY, Fu YW, Yang ZX (2019) Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse. Genome Biol 20(1):1\u20137","journal-title":"Genome Biol"},{"issue":"1","key":"5457_CR99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-37186-2","volume":"9","author":"H Chen","year":"2019","unstructured":"Chen H, Shi M, Gilam A, Zheng Q, Zhang Y, Afrikanova I, Li J, Gluzman Z, Jiang R, Kong LJ, Chen-Tsai RY (2019) Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIII. Sci Rep 9(1):1\u20135","journal-title":"Sci Rep"},{"issue":"5","key":"5457_CR100","doi-asserted-by":"publisher","first-page":"477","DOI":"10.15252\/emmm.201506039","volume":"8","author":"Y Guan","year":"2016","unstructured":"Guan Y, Ma Y, Li Q, Sun Z, Ma L, Wu L, Wang L, Zeng L, Shao Y, Chen Y, Ma N (2016) CRISPR\/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse. EMBO Mol Med 8(5):477\u2013488","journal-title":"EMBO Mol Med"},{"key":"5457_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0243-1","volume":"51","author":"JJ Sung","year":"2019","unstructured":"Sung JJ, Park CY, Leem JW et al (2019) Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs. Exp Mol Med 51:1\u20139","journal-title":"Exp Mol Med"},{"issue":"17","key":"5457_CR102","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.omtn.2019.05.019","volume":"6","author":"Z Hu","year":"2019","unstructured":"Hu Z, Zhou M, Wu Y, Li Z, Liu X, Wu L, Liang D (2019) ssODN-mediated in-frame deletion with CRISPR\/Cas9 restores FVIII function in hemophilia A-patient-derived iPSCs and ECs. Mol Ther Nucleic Acids 6(17):198\u2013209","journal-title":"Mol Ther Nucleic Acids"},{"issue":"12","key":"5457_CR103","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1111\/jth.15052","volume":"18","author":"AR Rezaie","year":"2020","unstructured":"Rezaie AR, Giri H (2020) Anticoagulant and signaling functions of antithrombin. J Thromb Haemost 18(12):3142\u20133153","journal-title":"J Thromb Haemost"},{"issue":"3","key":"5457_CR104","doi-asserted-by":"publisher","first-page":"eabj6901","DOI":"10.1126\/sciadv.abj6901","volume":"8","author":"JP Han","year":"2022","unstructured":"Han JP, Kim M, Choi BS, Lee JH, Lee GS, Jeong M, Lee Y, Kim EA, Oh HK, Go N, Lee H (2022) In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy. Sci Adv 8(3):eabj6901","journal-title":"Sci Adv"},{"key":"5457_CR105","first-page":"1","volume":"19","author":"YF Hu","year":"2022","unstructured":"Hu YF, Fang YH, Lai YR, Feng XQ, Xu SQ (2022) Application of gene therapy in hemophilia. Curr Med Sci 19:1\u20137","journal-title":"Curr Med Sci"},{"issue":"3","key":"5457_CR106","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/bfgp\/elz031","volume":"19","author":"J Sun","year":"2020","unstructured":"Sun J, Wang J, Zheng D, Hu X (2020) Advances in therapeutic application of CRISPR-Cas9. Brief Funct Genom 19(3):164\u2013174","journal-title":"Brief Funct Genom"},{"issue":"5","key":"5457_CR107","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/nrg.2016.28","volume":"17","author":"SQ Tsai","year":"2016","unstructured":"Tsai SQ, Joung JK (2016) Defining and improving the genome-wide specificities of CRISPR\u2013Cas9 nucleases. Nat Rev Genet 17(5):300\u2013312","journal-title":"Nat Rev Genet"},{"issue":"10","key":"5457_CR108","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/nmeth.3993","volume":"13","author":"WL Chew","year":"2016","unstructured":"Chew WL, Tabebordbar M, Cheng JK, Mali P, Wu EY, Ng AH, Zhu K, Wagers AJ, Church GM (2016) A multifunctional AAV\u2013CRISPR\u2013Cas9 and its host response. Nat Methods 13(10):868\u2013874","journal-title":"Nat Methods"},{"issue":"2","key":"5457_CR109","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","volume":"25","author":"CT Charlesworth","year":"2019","unstructured":"Charlesworth CT, Deshpande PS, Dever DP, Camarena J, Lemgart VT, Cromer MK, Vakulskas CA, Collingwood MA, Zhang L, Bode NM, Behlke MA (2019) Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med 25(2):249\u2013254","journal-title":"Nat Med"},{"issue":"1","key":"5457_CR110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-09693-x","volume":"10","author":"SR Ferdosi","year":"2019","unstructured":"Ferdosi SR, Ewaisha R, Moghadam F, Krishna S, Park JG, Ebrahimkhani MR, Kiani S, Anderson KS (2019) Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes. Nat Commun 10(1):1","journal-title":"Nat Commun"},{"issue":"5","key":"5457_CR111","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1182\/bloodadvances.2020001996","volume":"5","author":"G Pavani","year":"2021","unstructured":"Pavani G, Fabiano A, Laurent M, Amor F, Cantelli E, Chalumeau A, Maule G, Tachtsidi A, Concordet JP, Cereseto A, Mavilio F (2021) Correction of \u03b2-thalassemia by CRISPR\/Cas9 editing of the \u03b1-globin locus in human hematopoietic stem cells. Blood Adv 5(5):1137\u20131153","journal-title":"Blood Adv"},{"issue":"1","key":"5457_CR112","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13287-022-02768-5","volume":"13","author":"L Li","year":"2022","unstructured":"Li L, Yi H, Liu Z, Long P, Pan T, Huang Y, Li Y, Li Q, Ma Y (2022) Genetic correction of concurrent \u03b1-and \u03b2-thalassemia patient-derived pluripotent stem cells by the CRISPR-Cas9 technology. Stem Cell Res Ther 13(1):102","journal-title":"Stem Cell Res Ther"},{"issue":"21","key":"5457_CR113","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.omtm.2021.03.025","volume":"11","author":"LC Cosenza","year":"2021","unstructured":"Cosenza LC, Gasparello J, Romanini N, Zurlo M, Zuccato C, Gambari R, Finotti A (2021) Efficient CRISPR-Cas9-based genome editing of \u03b2-globin gene on erythroid cells from homozygous \u03b2039-thalassemia patients. Mol Ther Methods Clin Dev 11(21):507\u2013523","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"21","key":"5457_CR114","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.omtm.2021.02.022","volume":"11","author":"N Uchida","year":"2021","unstructured":"Uchida N, Drysdale CM, Nassehi T, Gamer J, Yapundich M, DiNicola J, Shibata Y, Hinds M, Gudmundsdottir B, Haro-Mora JJ, Demirci S (2021) Cas9 protein delivery non-integrating lentiviral vectors for gene correction in sickle cell disease. Mol Ther Methods Clin Dev 11(21):121\u2013132","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"5457_CR115","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ymthe.2020.09.001","volume":"29","author":"C Li","year":"2021","unstructured":"Li C, Wang H, Georgakopoulou A, Gil S, Yannaki E, Lieber A (2021) In vivo HSC gene therapy using a bi-modular HDAd5\/35++ vector cures sickle cell disease in a mouse model. Mol Ther 29(2):822\u2013837","journal-title":"Mol Ther"},{"issue":"Supplement 1","key":"5457_CR116","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1182\/blood-2022-166605","volume":"140","author":"RP Patel","year":"2022","unstructured":"Patel RP, Ghilardi G, Porazzi P, Yang S, Qian D, Pajarillo R, Wang M, Zhang Y, Schuster SJ, Barta SK, Nimmagadda A (2022) Clinical development of Senza5TM CART5: a novel dual population CD5 CRISPR-Cas9 knocked out anti-CD5 chimeric antigen receptor T cell product for relapsed and refractory CD5+ nodal T-cell lymphomas. Blood 140(Supplement 1):1604\u20131605","journal-title":"Blood"},{"key":"5457_CR117","first-page":"2020","volume":"23","author":"J Zhang","year":"2020","unstructured":"Zhang J, Hu Y, Yang J, Li W, Tian Y, Wei G, Zhang L, Zhao K, Qi Y, Tan B, Zhang M (2020) Development and clinical evaluation of non-viral genome specific targeted CAR T cells in relapsed\/refractory B-cell non-Hodgkin lymphoma. MedRxiv 23:2020\u20132009","journal-title":"MedRxiv"},{"issue":"4","key":"5457_CR118","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1089\/crispr.2021.0009","volume":"4","author":"E Vuelta","year":"2021","unstructured":"Vuelta E, Ordo\u00f1ez JL, Alonso-P\u00e9rez V, M\u00e9ndez L, Hern\u00e1ndez-Carabias P, Salda\u00f1a R, Sevilla J, Sebasti\u00e1n E, Munti\u00f3n S, S\u00e1nchez-Guijo F, Hern\u00e1ndez-Rivas JM (2021) CRISPR-Cas9 technology as a tool to target gene drivers in cancer: proof of concept and new opportunities to treat chronic myeloid leukemia. CRISPR J 4(4):519\u2013535","journal-title":"CRISPR J"},{"key":"5457_CR119","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/BLCTT.S230383","volume":"27","author":"M Narimani","year":"2019","unstructured":"Narimani M, Sharifi M, Jalili A (2019) Knockout of BIRC5 gene by CRISPR\/Cas9 induces apoptosis and inhibits cell proliferation in leukemic cell lines, HL60 and KG1. Blood Lymphat Cancer: targets and therapy 27:53\u201361","journal-title":"Blood Lymphat Cancer: targets and therapy"},{"issue":"1","key":"5457_CR120","doi-asserted-by":"publisher","first-page":"2081415","DOI":"10.1080\/2162402X.2022.2081415","volume":"11","author":"T Bexte","year":"2022","unstructured":"Bexte T, Alzubi J, Reindl LM, Wendel P, Schubert R, Salzmann-Manrique E, von Metzler I, Cathomen T, Ullrich E (2022) CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma. Oncoimmunology 11(1):2081415","journal-title":"Oncoimmunology"},{"issue":"21","key":"5457_CR121","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1182\/blood.2020006200","volume":"136","author":"M Naeimi Kararoudi","year":"2020","unstructured":"Naeimi Kararoudi M, Nagai Y, Elmas E, de Souza Fernandes Pereira M, Ali SA, Imus PH, Wethington D, Borrello IM, Lee DA, Ghiaur G (2020) CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Blood 136(21):2416\u20132427","journal-title":"Blood"},{"key":"5457_CR122","doi-asserted-by":"crossref","unstructured":"Chen X, Niu X, Liu Y, Zheng R, Yang L, Lu J, Yin S, Wei Y, Pan J, Sayed A, Ma X (2022) Long-term correction of hemophilia B through CRISPR\/Cas9 induced homology-independent targeted integration.\u00a0J Genet Genomics\u00a049(12):1114\u20131126","DOI":"10.1016\/j.jgg.2022.06.001"},{"issue":"18","key":"5457_CR123","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.omtm.2020.06.025","volume":"11","author":"Q Wang","year":"2020","unstructured":"Wang Q, Zhong X, Li Q, Su J, Liu Y, Mo L, Deng H, Yang Y (2020) CRISPR-Cas9-mediated in vivo gene integration at the albumin locus recovers hemostasis in neonatal and adult hemophilia B mice. Mol Ther Methods Clin Dev 11(18):520\u2013531","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"26","key":"5457_CR124","first-page":"2745","volume":"133","author":"L Wang","year":"2019","unstructured":"Wang L, Yang Y, Breton CA, White J, Zhang J, Che Y, Saveliev A, McMenamin D, He Z, Latshaw C, Li M (2019) CRISPR\/Cas9-mediated in vivo gene targeting corrects hemostasis in newborn and adult factor IX\u2013knockout mice. Blood J American Soc Hematol 133(26):2745\u20132752","journal-title":"Blood J American Soc Hematol"},{"issue":"48","key":"5457_CR125","doi-asserted-by":"publisher","first-page":"101948","DOI":"10.1016\/j.scr.2020.101948","volume":"1","author":"JJ Sung","year":"2020","unstructured":"Sung JJ, Park S, Choi SH, Kim J, Cho MS, Kim DW (2020) Generation of a gene edited hemophilia A patient-derived iPSC cell line, YCMi001-B-1, by targeted insertion of coagulation factor FVIII using CRISPR\/Cas9. Stem Cell Res 1(48):101948","journal-title":"Stem Cell Res"},{"issue":"6","key":"5457_CR126","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.stemcr.2019.04.016","volume":"12","author":"CY Park","year":"2019","unstructured":"Park CY, Sung JJ, Cho SR, Kim J, Kim DW (2019) Universal correction of blood coagulation factor VIII in patient-derived induced pluripotent stem cells using CRISPR\/Cas9. Stem Cell Rep 12(6):1242\u20131249","journal-title":"Stem Cell Rep"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05457-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05457-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05457-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T07:07:43Z","timestamp":1715584063000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05457-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":126,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["5457"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05457-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,22]]},"assertion":[{"value":"5 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}